This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




  Mobile version    RSS    Subscribe    Unsubscribe    Archive    Media Kit Sep. 13, 2012

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us  


 



PRESIDENT'S CORNER
Roslyn Mannon, MD

4 Ways Congress is Killing the Immuno Bill


In her latest blog post, AST President, Dr. Roslyn Mannon has strong words for Congress today and blames petty partisan bickering and institutional inactivity for reasons why the Immuno Bill hasn't been acted on. Check our her latest blog post now and read about how party politics may ruin any chance we have of seeing action this year on important legislation that will save lives. Read and comment on this blog .

 SOCIETY NEWS


Protecting patients against West Nile virus
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
West Nile virus has been circulating in most areas of the U.S. and transplant recipients have a higher rate of severe neurologic disease compared to the general population. Transplant patients need to take extra precautions and use personal protection measures against mosquitoes. This brochure by the CDC highlights the protection measures needed against this virus and provides useful information for both patients and physicians.



Submit abstracts now for AST's Cutting Edge of Transplantation (CEOT) 2013 meeting
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Not a clinical meeting, not a research meeting — simply the cutting edge of both. "B Cells from Bedside to Bench to Bedside: A Comprehensive Look at B Cells and Antibodies in Transplantation," will be held Feb. 14-16, 2013 in Phoenix, at the Sheraton Wild Horse Pass.

AST's first Cutting Edge of Transplantation (CEOT) meeting is a multi-expert view of the most important clinical and research problems in transplantation. Integrated clinical transplant and basic science talks define best approaches to management and research questions.

Abstract submission is now open. Clinical, basic and translational abstracts related to the meeting topic will be considered. Submit as many as you'd like before the Oct. 31 deadline.

Join clinical and basic science experts to address key management and research questions: What is the state of the field and the challenges to successfully transplanting sensitized patients? How does the immunobiology of B cells, plasma cells and antibody inform these challenges to clinical practice and suggest solutions? What are the best desensitization protocols and alternative therapies and their short- and long-term outcomes? Where are we in 'precision diagnosis' and continued monitoring of antibody-mediated rejection (AMR)?

Valentine's Day with AST: CEOT is about the joy of discovery. On Valentine's Day 2013, share that joy and discover the wild beauty of the desert with your loved one. Let the spirit of this ancient land breathe new energy into your lives together in a spectacular setting.




 TRANSPLANT NEWS


Hepatitis E virus: What transplant physicians should know
American Journal of Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Hepatitis E virus infection is an underdiagnosed disease in the developed world. In pediatric and adult organ transplant patients HEV infection can cause chronic hepatitis, which can lead to cirrhosis. Extra-hepatic manifestations, such as neurological symptoms and kidney injury, have been also reported in transplant patients. In this comprehensive minireview, researchers summarize the current knowledge on HEV infection in transplant patients, that is, its prevalence, incidence, natural history and therapy. More

C1qScreen™: A New Research Tool for AMR Risk
Identify Antibodies That May Compromise Graft Survival
  • Detect Presence of Complement Fixing Antibodies
  • Investigate risk of developing Antibody Mediated Rejection (AMR)
Request a Complimentary Sample Kit!
FREE SAMPLE

For Research Use Only. Not for use in diagnostic procedures.


Doctors win Lasker awards for inventing liver transplant; cell biology
The Associated Press via NBC News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Surgeons who helped make liver transplants an almost everyday life-saving event, a team that shed light on the the inner workings of cells, and genetics experts who have acted as leaders in biomedical science have won prestigious Lasker awards, the Albert and Mary Lasker Foundation announced recently. The Lasker award for clinical medical research was shared by Dr. Thomas Starzl of the University of Pittsburgh and Dr. Roy Calne, an emeritus professor at Cambridge University, for developing liver transplantation.

Related articles:
Lasker Awards to honor 7 scientists (The New York Times)
Pioneering Pittsburgh transplant surgeon Starzl receives Lasker Award (Pittsburgh Post-Gazette)
More

Survival excellent following living donor liver transplantation for acute liver failure
Medical News Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Patients in Japan who underwent living donor liver transplantation for acute liver failure were classified as having excellent outcomes, with 10-year survival at 73 percent. The findings suggest that the type of liver disease or treatment plan does not affect long-term patient survival following LDLT. Donor and patient age, however, does impact long-term outcome post-transplant. More



New immunosuppressants in pediatric solid organ transplantation
Current Opinion in Organ Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
There are currently trials underway investigating the use of eculizumab and bortezomib for treatment of antibody-mediated rejection as well as utilizing these agents as part of desensitization protocols. Minimal (or even monotherapy) maintenance immunosuppression regimens include monoclonal antibodies and fusion receptor proteins targeting different pathways (CD40–CD154, CD28–CD80/86, and LFA3–CD2 pathway). Phase III randomized controlled trials in adults are required before embarking on treatment of children. More

Heart failure group focused on devices
MedPage Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Miniaturized ventricular assist devices and other novel pieces of equipment will take the spotlight here at the Heart Failure Society of America meeting against a backdrop of tension over standardizing performance in the field. VAD pumps have gotten progressively smaller and more convenient for patients over time — to the point where they are considered as a heart transplant alternative in some circumstances. More

Athena Diagnostics

Genetic testing can be a cost-effective way to increase the number of living related donor transplants. Mutational analysis may help direct long-term treatment plans, including pre-operative screening of potential kidney transplant recipients and living related donors.
more


Urinary pathogens changing in renal transplant patients
Renal & Urology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Over the past decade, gram-negative organisms have become more prevalent when organisms are isolated from the urine of renal transplant recipients, and resistance to levofloxacin and ceftriaxone has increased among Escherichia coli, the most frequently isolated urinary pathogen in these patients, a new study suggests. More

Gastroesophageal reflux disease-induced aspiration injury following lung transplantation
Current Opinion in Organ Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Recent findings support ubiquitous testing for GERD or aspiration in patients with end-stage lung disease both pretransplant and posttransplant and demonstrate that fundoplication can safely and effectively protect these patients from the ongoing injury of GERD-induced pulmonary injury. More

Some transplant candidates need more imaging
MedPage Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A subgroup of patients awaiting a kidney transplant could benefit from closer surveillance by SPECT myocardial perfusion imaging, researchers suggested. Of the 133 patients in the study who underwent screening before renal transplant from 2003 to 2011, 6 percent developed new ischemia or infarct during an average follow-up of 5 years, according to Dr. Sapna Legha, of Allegheny General Hospital in Pittsburgh, and colleagues. More
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Sept. 6, 2012
Aug. 31, 2012
Aug. 23, 2012
Aug. 16, 2012






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063